Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry

Adam, René; McMaster, P; O’Grady, John; Castaing, Denis; Klempnauer, Jürgen; Jamieson, Neville V.; Neuhaus, P.; Lerut, Jan; Salizzoni, Mauro; Pollard, S.; Mühlbacher, Ferdinand; Rogiers, Xavier; Valdecasas, Juan Carlos García; Berenguer, J; Jaeck, Daniel; González, Enrique Moreno

doi:10.1016/j.lts.2003.09.018

Cited by 525 publications

(369 citation statements)

References 5 publications

Supporting

Mentioning

330

Contrasting

Unclassified

Order By: Relevance

“…1 Regretfully, recurrence of HCV infection is universal after LT, 2 and disease progression is significantly faster in immunosuppressed than in immunocompetent individuals. In liver transplant recipients, chronic HCV infection may lead to cirrhosis in as much as 30% of individuals only 5 years after LT. [3][4][5] Once liver cirrhosis is established, the cumulative probability of developing clinical decompensation is close to 50% 1 year after diagnosis and, more importantly, survival after decompensation is extremely short.…”

Section: Hronic Hepatitis C Virus (Hcv) Infection Leadingmentioning

confidence: 99%

Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation

et al. 2006

View full text Add to dashboard Cite

Liver biopsy is essential in the follow-up of HCV-infected liver transplant recipients. The aim of this study was to prospectively compare percutaneous (PLB) versus transjugular liver biopsy (TLB) in the assessment of liver damage. We also explored the diagnostic value of hepatic venous pressure gradient (HVPG) to identify patients at risk of severe HCV disease recurrence after liver transplantation (LT). One hundred sixteen paired PLB and TLB (with HVPG measurement) were performed 3 or 12 months after LT in 80 patients. Concordance for necroinflammation and fibrosis was fair or good, particularly 1 year after LT (kappa > 0.6). At this point, a significant positive association was seen between the median HVPG and the fibrosis stage C hronic hepatitis C virus (HCV) infection leading to liver cirrhosis and hepatocellular carcinoma is the main indication for liver transplantation (LT) in Western countries and Japan. 1 Regretfully, recurrence of HCV infection is universal after LT, 2 and disease progression is significantly faster in immunosuppressed than in immunocompetent individuals. In liver transplant recipients, chronic HCV infection may lead to cirrhosis in as much as 30% of individuals only 5 years after LT. [3][4][5] Once liver cirrhosis is established, the cumulative probability of developing clinical decompensation is close to 50% 1 year after diagnosis and, more importantly, survival after decompensation is extremely short. 6 As a result of this accelerated course of HCV infection, longterm graft and patient survival are significantly reduced in patients undergoing LT for HCV-related cirrhosis compared with other groups. 7 Frequent liver biopsies are essential to monitor HCV-induced liver damage and are part of the routine follow-up of HCV-infected liver transplant recipients. Early histological damage after transplantation correlates with long-term outcome; in fact, the presence of significant liver fibrosis in 1-year liver biopsies identifies patients at high risk of graft loss. 3,8 In addition, assessment of liver damage is relevant to adopt therapeutic decisions, particularly because of the low efficacy and high incidence of adverse events of current antiviral therapy in this group of patients. 3,9,10

show abstract

Section: Hronic Hepatitis C Virus (Hcv) Infection Leadingmentioning

confidence: 99%

Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation

et al. 2006

View full text Add to dashboard Cite

show abstract

“…4 Liver retransplant is associated with lower patient and graft survival rates than equivalent rates after primary transplant. The main reasons for poor outcomes after reLTx are infections, septic complications, multiple organ failure, 5,6,14,15 and bleeding complications. 6,14 The overall 1-, 3-, 5-and 10-year survival rates after the first reLTx are 66%, 61%, 57%, and 47%.…”

Section: Introductionmentioning

confidence: 99%

“…The main reasons for poor outcomes after reLTx are infections, septic complications, multiple organ failure, 5,6,14,15 and bleeding complications. 6,14 The overall 1-, 3-, 5-and 10-year survival rates after the first reLTx are 66%, 61%, 57%, and 47%. 1,4,[7][8][9][10][15][16][17][18] Given the shortage of organs available for transplant, there is an ethical question of equity in the distribution of this scarce resource; it practically denies access to patients waiting for their first transplant.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2014

Exp Clin Transplant

View full text Add to dashboard Cite

Liver retransplant is the only treatment for patients with irreversible graft failure. However, given the severe shortage of organs, there is an ethical question of equity in the distribution of this resource. Liver retransplant is more expensive and is associated with lower patient/graft survival rates than equivalent rates after primary transplant. Both primary nonfunction and hepatic artery thrombosis account for nearly all cases of early liver retransplant. Late indications of liver retransplantinclude chronic rejection, biliary complications, or recurrence of primary disease such as hepatitis C, autoimmune hepatitis, and primary sclerosing cholangitis. Donor data are not available when a patient is listed for liver retransplant; therefore, prognostic factors related to the recipient is a more practical way of making the decision to offer liver retransplant is made. In the Model of End-stage Liver Disease era liver retransplant for "late" indications is more complex and selection criteria are more stringent. We review the literature for predictive factors influencing outcome of liver retransplant, especially in those with recurrent disease.

show abstract

“…No obstante, en occidente el THDV se ha convertido en una alternativa más dentro del organigrama de los programas de donación. Hasta la fecha, el THDV tiene aplicaciones limitadas básicamente por el riesgo del donante, que puede terminar con morbilidad y mortalidad significante [1][2][3][4] . Además, los resultados publicados de las series de THDV son frecuentemente controvertidas, al estar asociada esta modalidad de trasplante a una morbilidad incrementada y a una supervivencia en ocasiones disminuida.…”

unclassified

Las complicaciones biliares en el trasplante hepático de donante vivo no afectan los resultados a largo plazo

et al. 2013

View full text Add to dashboard Cite

Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry

Cited by 525 publications

References 5 publications

Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation

Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation

Untitled

Las complicaciones biliares en el trasplante hepático de donante vivo no afectan los resultados a largo plazo

Contact Info

Product

Resources

About